Article Per Year (5 Year)
p-Index From 2021 - 2026
0.61
P-Index
This Author published in this journals
All Journal Pharmaceutical Journal of Indonesia Hubungan Tingkat Pengetahuan Petugas Pengelola Obat dengan Tingkat Ketersediaan Obat Di Puskesmas Kota Malang SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL
Rizal Rizal
Poltekkes Kemenkes Maluku
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health Social Sciences

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Side Effects Rizal Rizal
Pharmaceutical Journal of Indonesia Vol. 6 No. 2 (2021)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.pji.2021.006.02.1

Abstract

Aim: WHO projects that diabetes will be the seventh leading cause of death in 2030. One of the macrovascular of diabetes is cardiovascular (CV) diseases, reported incidence of heart failure in diabetic patients is twice greater than control subjects and intensive use of antidiabetic drugs in diabetic patients increase CV mortality. This review will discusses the effect of DPP4 inhibitors (DPP-4i) on CV outcomes.Data sources: PubMed 32 journals, Google Scholar 17 journals, BioMed Central 5 journals and others 1 journalMethod: A systemic search of all English-language articles up to 2020 was conducted using the following terms: dipeptidyl peptidase-4 inhibitors, sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin, gemigliptin, anagliptin, teneligliptin, alogliptin, trelagliptin, omarigliptin, cardiovascular, and mechanism on cardiovascular diseases.Results: Positive effect on CV of DPP-4i mediated by activate PI3K, CAMP, eNOS and PKA, and negative effect because their effects in modulate SP, peptide YY, and neuropeptide Y. CV outcomes of DPP-4i versus placebo are variated for MACEs, which are reported on sitagliptin HR 0.98, 95% CI 0.89 to 1.08; Vildagliptin RR 0.82, 95% CI 0.61 to 1.11; Saxagliptin HR 1.00, 95% CI, 0.89 to 1.12; Linagliptin  HR 0.78, 95% CI, 0.55 to 1.12; Alogliptin HR 0.85, CI 95%, 0.66 to 1.10; and Omarigliptin HR=0.85, CI 95%, 0.66-1.10.Conclusion: Based on the mechanism DPP-4i inhibitors have either cardioprotective actions or poorer outcomes on CV because their activities are connected with the inhibition of various substrates. DPP-4i sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin, and omarigliptin did not significantly increase of MACE (major adverse cardiac events).
Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Side Effects Rizal Rizal
Pharmaceutical Journal of Indonesia Vol. 6 No. 2 (2021)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.pji.2021.006.02.1

Abstract

Aim: WHO projects that diabetes will be the seventh leading cause of death in 2030. One of the macrovascular of diabetes is cardiovascular (CV) diseases, reported incidence of heart failure in diabetic patients is twice greater than control subjects and intensive use of antidiabetic drugs in diabetic patients increase CV mortality. This review will discusses the effect of DPP4 inhibitors (DPP-4i) on CV outcomes.Data sources: PubMed 32 journals, Google Scholar 17 journals, BioMed Central 5 journals and others 1 journalMethod: A systemic search of all English-language articles up to 2020 was conducted using the following terms: dipeptidyl peptidase-4 inhibitors, sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin, gemigliptin, anagliptin, teneligliptin, alogliptin, trelagliptin, omarigliptin, cardiovascular, and mechanism on cardiovascular diseases.Results: Positive effect on CV of DPP-4i mediated by activate PI3K, CAMP, eNOS and PKA, and negative effect because their effects in modulate SP, peptide YY, and neuropeptide Y. CV outcomes of DPP-4i versus placebo are variated for MACEs, which are reported on sitagliptin HR 0.98, 95% CI 0.89 to 1.08; Vildagliptin RR 0.82, 95% CI 0.61 to 1.11; Saxagliptin HR 1.00, 95% CI, 0.89 to 1.12; Linagliptin  HR 0.78, 95% CI, 0.55 to 1.12; Alogliptin HR 0.85, CI 95%, 0.66 to 1.10; and Omarigliptin HR=0.85, CI 95%, 0.66-1.10.Conclusion: Based on the mechanism DPP-4i inhibitors have either cardioprotective actions or poorer outcomes on CV because their activities are connected with the inhibition of various substrates. DPP-4i sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin, and omarigliptin did not significantly increase of MACE (major adverse cardiac events).
COMPLICATIONS OF DISEASES AND SERUM CREATININE LEVELS IN DIABETIC PATIENTS Rizal Rizal; Syawal Alfikry Kaimudin; Wulan Panduwi Melasari
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 1 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i1.8605

Abstract

Diabetes mellitus, a metabolic disease, is a predisposing factor for diabetic nephropathy. This condition is defined by renal damage and hypercreatininemia in individuals with diabetes. Diabetic nephropathy is a multifactorial condition, with comorbidities playing a significant role in its pathogenesis. The purpose of this study was to determine the association between complicatin of diseases and serum creatinine levels among Diabetes Mellitus patients at the Nania Community Health Center, Ambon. The study adopted a cross-sectional design. A simple random sample was drawn for the study. The measurement of serum creatinine concentration is carried out using the Jaffé Reaction (Kinetic Method) at the Laboratory of the Maluku Province Special Regional Hospital. Chi-Square test was used to statistically analyze the data. A total of 30 patients were included in this study. Of these, 17 patients (56.7%) had complicatin, 10 patients (33.3%) had abnormal creatinine levels, and 7 patients (23.3%) had normal creatinine levels. Furthermore, 13 patients (43.3%) without complication had normal creatinine levels. The results of the Chi-Square test demonstrated a statistically significant association (p = 0.001) was found between complication and serum creatinine levels in Diabetes Mellitus patients. The results of statistical analysis demonstrated a statistically significant association (p = 0.001) between complication of diseases and serum creatinine concentration in patients with Diabetes Mellitus. This suggests that the presence of complication increases the likelihood of abnormal serum creatinine, consequently raising the possibility of diabetic nephropathy.
Co-Authors Syawal Alfikry Kaimudin wulan panduwi melasari